Guidance

Hepatitis B vaccine: patient group direction template

Patient group direction (PGD) template to help provide hepatitis B vaccine to individuals before and after exposure to hepatitis B.

• From: UK Health Security Agency
• Published: 17 May 2017
• Last updated: 3 June 2025
  Show all updates

  1. 3 June 2025

     Added version 6 - see page 3 for change history.

  2. 29 January 2025

     Added notice of extension.

  3. 10 October 2023

     Added version 05.00 – see page 2 for change history.

  4. 15 October 2021

     Added v04.00.

  5. 12 April 2021

     Added version 03.00. See page 2 for change history.

  6. 2 April 2019

     Replaced PGD template with updated version.

  7. 17 May 2017

     First published.

Applies to England

Documents

Hepatitis B vaccine: patient group direction template

Ref: UKHSA gateway number GOV-18483

MS Word Document, 241 KB

This file may not be suitable for users of assistive technology.

Request an accessible format

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@ukhsa.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This patient group direction (PGD) template supports the provision of hepatitis B vaccine to individuals considered at increased risk of exposure to hepatitis B virus, at increased risk of complications of hepatitis B disease, or after a potential exposure to hepatitis B virus. It may also be used to vaccinate children with incomplete or unknown immunisation status against hepatitis B.

The hepatitis B PGD version 6.0 is valid from 1 July 2025 to 30 April 2028.

Practitioners must not use this PGD template until it has been authorised in Section 2. This is a legal requirement (see Human Medicines Regulations 2012). Practitioners should follow local policy or procedures to access authorised PGD documents.

This PGD template should be used with reference to current national guidance, the Green Book, and summary of product characteristics for the vaccine.